Dr. Lior Shaltiel reports

NUREXONE AND PARTICLE METRIX ANNOUNCE COLLABORATION IN EXTRACELLULAR VESICLES ANALYSIS USING STATE-OF-THE-ART ANALYTIC DEVICE

Nurexone Biologic Inc. has formed a pioneering collaboration with the German company Particle Metrix, a leading provider of particle analysis devices. In connection with the collaboration, a highly advanced nanoparticle tracking analysis instrument (NTA) has been recently placed at Nurexone's laboratory, which is an important milestone in the expansion of Nurexone's production and analytic processes.

The newly acquired NTA, which is the first of its kind in Israel, is equipped with state-of-the-art capabilities, including nanoparticle tracking analysis and advanced co-localization technology. The new system is a ZetaView Twin laser system PMX-230 using wavelengths of 520 and 640 nanometres for size, concentration, fluorescence, co-localization and Zeta potential analysis. As part of the collaboration, the two companies will share analytical data between them in order to improve the co-localization performance of the device at these two wavelengths.

Nurexone plans to leverage the capabilities of the advanced NTA to validate its methodology for analysis of loaded exosomes, a vital part of the development process of its ExoPTEN drug, targeted at the $2.9-billion global market for patients with acute spinal cord injury. In line with its business strategy of monetizing its knowledge and capabilities, Nurexone will also be able to offer the NTA services to other companies developing exosome-based therapies for other indications.

"We firmly believe that exosome-based therapies have the potential to be the next frontier in drug delivery systems and are thrilled to collaborate with Nurexone and deliver in Israel for the first time a state-of-the-art ZetaView Twin laser system," noted Dr. Clemens Helmbrecht, managing director of Particle Metrix.

"We are delighted to integrate this one-of-its-kind system into our analytics procedure and quality control, further advancing our capabilities for analyzing exosomes loaded with therapeutic cargo," stated Dr. Lior Shaltiel, chief executive officer of Nurexone. "We anticipate a transformative impact on our quality process in order to develop the highest quality of life-changing therapies for central nervous system patients worldwide."

About Nurexone Biologic Inc.

Nurexone Biologic is a TSX Venture Exchange-listed pharmaceutical company that is developing a platform for biologically guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.

ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. Nurexone is translating the treatment to humans, and the company holds an exclusive worldwide licence from the Technion and Tel Aviv University for the development and commercialization of the technology.

We seek Safe Harbor.